Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 4Terminated 2

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Hyperuricemia 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Allopurinol × Clear all
NCT02953509 2025-05-29

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Gilead Sciences

Phase 1/2 Terminated
178 enrolled 33 charts
Lymphoid

Lymphoma, Non-Hodgkin

NCT00607152 2014-05-08

Rasburicase (Fasturtec) Registration Trial

Sanofi

Phase 3 Terminated
10 enrolled

Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡